Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
102.52
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
↗
June 02, 2021
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high.
Via
Investor's Business Daily
BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients
↗
June 02, 2021
BriaCell Therapeutics Corp (NASDAQ: BCTX) has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
↗
June 01, 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...
Via
Benzinga
Week In Review: Nikang Raises $200 Million From US And China Investors
↗
May 29, 2021
NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors. NiKang was originally incubated by CBC Group (C-Bridge Capital) in...
Via
Talk Markets
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
↗
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Incyte to Present at Upcoming Investor Conferences
May 20, 2021
From
Incyte
Via
Business Wire
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
May 19, 2021
From
Incyte
Via
Business Wire
Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing Up Regulatory Submissions
↗
May 17, 2021
Incyte Corporation (NASDAQ: INCY) has announced positive topline results from its pivotal Phase 3 TRuE-V trial program evaluating ruxolitinib cream in...
Via
Benzinga
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
May 17, 2021
From
Incyte
Via
Business Wire
The QQQ Was Hammered Again Today. Here's Why.
↗
May 12, 2021
U.S. indices were trading lower across the board Wednesday after CPI data showed an increase in U.S. inflation, which has weighed on stocks.
Via
Benzinga
Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
May 12, 2021
From
Incyte
Via
Business Wire
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
May 11, 2021
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
↗
May 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...
Via
Benzinga
Incyte Corp (INCY) Q1 2021 Earnings Call Transcript
↗
May 04, 2021
INCY earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance
↗
May 04, 2021
Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of...
Via
Benzinga
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
↗
May 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Recap: Incyte Q1 Earnings
↗
May 04, 2021
Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 123.43% year over year to $0.67, which...
Via
Benzinga
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 04, 2021
From
Incyte
Via
Business Wire
Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021
May 03, 2021
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
April 27, 2021
From
Incyte
Via
Business Wire
Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies
↗
April 23, 2021
Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream...
Via
Benzinga
Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
April 23, 2021
From
Incyte
Via
Business Wire
Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
April 23, 2021
From
Incyte
Via
Business Wire
Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
April 20, 2021
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
↗
April 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...
Via
Benzinga
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
April 19, 2021
From
Incyte and MorphoSys AG
Via
Business Wire
Incyte to Report First Quarter Financial Results
April 13, 2021
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
↗
April 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc...
Via
Benzinga
Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal
↗
April 08, 2021
Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) have reported results from the COV-BARRIER Phase 3 study ...
Via
Benzinga
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
↗
April 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) AngioDynamics, Inc. (NASDAQ...
Via
Benzinga
Topics
Intellectual Property
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
